SF3B1
Splicing Factor 3b Subunit 1
SF3B1 is the largest subunit of the spliceosome factor 3b (SF3B) complex and functions by serving as a core component of the 17S U2 SnRNP complex of the spliceosome. The spliceosome removes introns from precursor mRNA (premRNA) and generates mature, spliced mRNAs. SF3B1 mutations induce common and tumor-specific splicing aberrations[1].
All Product Categories
-
SF3B1 Related Products (11)
Related Products (11)
-
Antibodies (1)
- 1
-
H3B-8800
0 ImagesH3B-8800 is a potent and orally active SF3B splicing modulator. H3B-8800 direct interaction with the SF3b complex and shows anti-cancer activity. H3B-8800 has the potential for the research of acute myeloid leukemia (AML) with SF3B1 mutant.
-
Spliceostatin A
0 ImagesCat. No.: HY-16466CAS No.: 391611-36-2Spliceostatin A, the FR901464 (HY-16212) methylated derivative, is a potent anti-tumor agent. Spliceostatin A inhibits splicing and promotes pre-mRNA accumulation by binding SF3B1. SF3B1 is a subcomplex of U2 small nuclear ribonucleoprotein in the spliceosome. Spliceostatin A induces Apoptosis in chronic lymphocytic leukemia (CLL) cells.
-
WX-02-23
0 ImagesWX-02-23 is a small-molecule probe that stereoselectively and site-specifically binds to C258 of FOXA1 and C1111 of SF3B1. WX-02-23 remodels FOXA1's chromatin binding and pioneer activity in a DNA-dependent manner, disrupts spliceosome assembly, and enhances the thermal stability of SF3B1. WX-02-23 inhibits tumor cell proliferation and induces apoptosis. WX-02-23 can be used for research on cancers such as prostate cancer.
-
WX-02-43
0 ImagesWX-02-43 is a weak covalent inhibitor of SF3B1, and is the (1S,3R) enantiomer of WX-02-23 (HY-168534). WX-02-43 cannot effectively covalently modify the C258 site in the DNA-binding domain of FOXA1, and its inhibitory activity against SF3B1 is also weaker than that of WX-02-23. WX-02-43 serves as a negative control probe that fails to remodel the chromatin binding pattern and transcriptional activity of FOXA1. WX-02-43 can be used in studies on cancers such as prostate cancer to verify the specific effects of WX-02-23 on FOXA1 and SF3B1 targets.
-
Sudemycin K
0 ImagesCat. No.: HY-122637CAS No.: 2071636-70-7Sudemycin K is a selective splicing inhibitor targeting SF3B1. Sudemycin K blocks U2 snRNP recognition of branch point sequences in pre-mRNA, inducing tumor-specific splicing deregulation and apoptosis. Sudemycin K is promising for research of SF3B1-mutated malignancies such as chronic lymphocytic leukemia (CLL) and myelodysplastic syndromes (MDS).
-
Sudemycin E
0 ImagesCat. No.: HY-120907CAS No.: 1197054-49-1Sudemycin E is an analog of FR901464 (HY-16212). Sudemycin E can induce reversible changes in alternative splicing and abnormalities in chromatin modifications by binding to SF3B1, a component of the U2 small nuclear ribonucleoprotein (snRNP), thereby leading to the death of cancer cells. Sudemycin E has anti-tumor activity and can be used in tumor research.
-
18-Deoxyherboxidiene
0 ImagesCat. No.: HY-133924CAS No.: 1200128-66-0Synonyms: RQN-18690A18-Deoxyherboxidiene (RQN-18690A) is a potent angiogenesis inhibitor. 18-Deoxyherboxidiene targets SF3b, a spliceosome component that is a subcomplex of the U2 small nuclear ribonucleoprotein (snRNP) in the spliceosome. 18-Deoxyherboxidiene inhibits the migration and tube formation of human umbilical vein endothelial cells (HUVECs) without significant cell toxicity. 18-Deoxyherboxidiene has the potential for cancer research.
-
Pladienolide B (Standard)
0 ImagesCat. No.: HY-16399RCAS No.: 445493-23-2Pladienolide B (Standard) is the analytical standard of Pladienolide B (HY-16399). This product is intended for research and analytical applications. Pladienolide B is a potent cancer cell growth inhibitor that targets the SF3B1 subunit of the spliceosome. Pladienolide B exerts antitumor activities mediated through the inhibition of pre-mRNA splicing. Pladienolide B induces apoptosis.
- 1
